NetworkNewsBreaks

TuesdayMay 24, 2022 2:51 pm

NetworkNewsBreaks – HouseBit Corp. Unveils New Ownership, Occupancy Model with Completion of First Fully Tokenized Property in Miami

HouseBit, based in Miami, has completed the first fully digital, real estate tokenization on a property in downtown Miami; the transaction used cryptographic decentralized blockchain technology. Miami-based International Realty Group, a Florida- licensed, full-service boutique real estate brokerage specializing in the luxury market, was also involved in the transaction. According to the announcement, the tokenization involved the combination of HouseBit’s patent-pending technology and a land trust created specifically for the property, which issued 1,000 ownership tokens, including a single occupancy non-fungible token (“NFT”), which provides the right to occupy the property. The other ownership tokens represented  proportional ownership in the…

Continue Reading

TuesdayMay 24, 2022 2:19 pm

NetworkNewsBreaks – SRAX Inc. (NASDAQ: SRAX) Shares Company Presentations, Keynote Addresses from 2022 Sequire Fintech Conference

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS (“SaaS”) platform, is making replays from its 2022 Sequire Fintech Conference presentation available. SRAX hosted the virtual investor event on May 19, 2022. During the conference, premier fintech stock market companies made key presentations to investor attendees; industry experts also provided keynote addresses during the event. The event was sponsored by Apex Fintech Solutions, Banxa Holdings Inc., Usio Inc. and Newtek Business Services Corp. According to the announcement, those interested can view the keynote address, panel discussions and company presentations…

Continue Reading

TuesdayMay 24, 2022 2:08 pm

NetworkNewsBreaks – HIVE Blockchain Technologies Ltd. (NASDAQ: HIVE) (TSX.V: HIVE) (FSE: HBF) Announces 5:1 Share Consolidation

HIVE Blockchain Technologies (NASDAQ: HIVE) (TSX.V: HIVE) (FSE: HBF) today announced that, further to its May 10 press release, the company will be proceeding with the consolidation of its common shares on the basis of five pre-consolidation common shares for one post-consolidation common share. The common shares will commence trading on the TSX Venture Exchange (“TSXV”) and Nasdaq on a post-consolidation basis effective at the opening of the market on May 24, 2022. Completion of the consolidation is subject to receipt of all necessary regulatory approvals, including TSXV approval and pursuant to the Business Corporations Act (British Columbia) and the…

Continue Reading

TuesdayMay 24, 2022 1:13 pm

NetworkNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Announces Issuance of Circular, Incentive Plan and Granting of PSUs

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced that it has issued a management information circular in respect of the annual general meeting of shareholders to be held on June 23, 2022. The circular is available on the company’s profile on SEDAR at www.SEDAR.com. In addition, to provide added flexibility to its executive compensation program, FSD Pharma on May 16, 2022, adopted an equity incentive plan (the “EIP”) pursuant to which it may grant shares, restricted share units, performance share units (“PSUs”) and…

Continue Reading

TuesdayMay 24, 2022 11:46 am

NetworkNewsBreaks – Global PayEX Participates at Finovate Spring 2022, Shines Spotlight on Proprietary AR Solutions

Global PayEX, a U.S.-headquartered B2B fintech that powers large corporations and mid-sized companies to bring working capital efficiencies via accounts receivable (“AR”) and accounts payable (“AP”) automation, participated in the Finovate Spring 2022 event. At the event, the company focused on its end-to-end, native-cloud, data-driven AR software solutions. According to the announcement, the company, which is backed by J.P. Morgan, has processed more than $50 billion in transactions. Its proprietary artificial intelligence (“AI”) and machine-learning (“ML”) offerings have built a reputation for delivering remarkable actionable insights for users, which include global multinationals 3M, Bridgestone, Huhtamaki, Stanley Black & Decker, GlaxoSmithKline…

Continue Reading

TuesdayMay 24, 2022 11:29 am

NetworkNewsBreaks – EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF) Schedules Conference Call to Discuss Q1 2022 Financial Results, Enters Acquisition Agreement

EverGen (TSX.V: EVGN) (OTCQB: EVGIF), Canada’s renewable natural gas (“RNG”) infrastructure platform, will releases its 2022 first-quarter financial results after market close today, May 24, 2022. In addition, the company will host a Zoom conference call to discuss company financial results and corporate updates on Wednesday, May 25. The Zoom event will begin at 10 a.m. ET. EverGen CEO Chase Edgelow will lead the call. In addition, EverGen signed a definitive agreement to acquire 50% interest in a portfolio of RNG development projects, known as Project Radius and owned by Northeast Renewables LP. The acquisition gives EverGen entry into the…

Continue Reading

TuesdayMay 24, 2022 10:37 am

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at H.C. Wainwright Global Investment Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its CEO John Climaco will be participating at the H.C. Wainwright Global Investment Conference. The event is slated to take place May 23-26, 2022, virtually and in-person in Miami, Florida. A video webcast of Climaco’s presentation is now accessible for viewing on-demand for registered attendees and will be available on the company’s website. Following the event, the webcast replay will be archived for 90 days. In addition, CNSP management will be…

Continue Reading

MondayMay 23, 2022 1:49 pm

NetworkNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Among Most Powerful of Chemotherapy Drugs

CNS Pharmaceuticals’ (NASDAQ: CNSP) novel anthracycline Berubicin, which has been developed to treat diseases with unmet need such as the deadly glioblastoma (“GBM”), appears to be the first anthracycline chemotherapy agent to successfully cross the blood-brain barrier in targeting tumors of the central nervous system. “Berubicin was the drug candidate subject of a small-scale phase 1 clinical trial in 2006 that evaluated its safety, which was notable because one of the two dozen evaluated patients emerged cancer-free and has remained so over the subsequent 16 years. Nearly half of the trial’s patients experienced a statistically significant improvement in clinical benefit.…

Continue Reading

MondayMay 23, 2022 1:40 pm

NetworkNewsBreaks – Silo Pharma Inc. (SILO) Bringing Hope to Patients Suffering from Alzheimer’s and Potentially Other Ailments

Silo Pharma (OTCQB: SILO) is exploring the efficacy of ketamine in treating patients suffering from both Alzheimer’s and Parkinson’s disease. With more than 80% of Parkinson’s patients and 75% of Alzheimer’s patients experiencing dysphagia, difficulty or complete inability to swallow, last year, SILO entered into a joint venture with Zylö Therapeutics. Under the collaboration, the companies will explore an innovative technology – ZTI’s Z-pod transdermal technology – to develop a ketamine delivery system for those suffering from dysphagia. “In October 2021, Silo entered into a sponsored research agreement with Columbia University incorporating the work of Dr. Christine Ann Denny. According…

Continue Reading

MondayMay 23, 2022 1:12 pm

NetworkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Partners to Help Accelerate Regulatory Pathway of CYB003

Cybin (NYSE American: CYBN) (NEO: CYBN) is moving forward with its phase 1/2a clinical trial of its proprietary deuterated psilocybin, CYB003, which, previous research shows, has the potential to effectively treat major depressive disorder (“MDD”) with significant advantages over classic psilocybin. MDD impacts over 264 million people worldwide, 1/3 to 1/2 of whom demonstrate an inadequate response to antidepressant drug treatment. Against this backdrop, Cybin focuses on finding solutions for those whose lives are impacted by MDD and other mental and emotional disorders. “The company recently completed in vivo preclinical studies of CYB003. The company plans to file an investigational…

Continue Reading